How Gold Carding Programs Are Reducing Prior Auth Requirements
Prior authorization consumes an average of 14.6 hours per physician per week, according to AMA survey data. A growing number of states have looked at that number and decided the right response isn't a faster portal — it's removing the requirement entirely for physicians who've already proven they don't need the oversight.
That's the logic behind gold carding. It's the most structurally interesting PA reform of the last five years, and it's spreading faster than most people in healthcare administration realize.
What Gold Carding Actually Is
Gold carding exempts providers from prior authorization requirements for specific procedures or medications when their historical approval rate clears a defined threshold — typically 90% or higher over a 6-month review period.
The premise is simple: if a physician's PA requests are approved 9 out of 10 times, what is the 10th review actually accomplishing? At that approval rate, the review process is generating administrative cost on both sides of the transaction without producing meaningful utilization control. Gold carding says: trust the track record.
It's worth being precise about what's exempted. Gold carding typically applies per service category, not as a blanket physician exemption. A rheumatologist might earn gold card status for biologic PAs while still being subject to prior auth for other service types. The exemption is specific, evidence-based, and revocable if approval rates drop.
Texas HB 3459: The Model Everyone Is Copying
Texas passed HB 3459 in 2021, making it the first state to codify gold carding into law. The statute requires commercial health benefit plans to exempt providers who meet the 90% approval rate threshold over a 6-month look-back period. Payers must notify qualifying providers within 30 days and cannot require PA for covered services during the exemption period.
The law also includes anti-gaming provisions. Payers can't narrow coverage criteria mid-cycle to artificially deflate approval rates. Providers lose their exemption if their approval rate drops below the threshold in a subsequent review period. And the exemption is drug-and-procedure-specific — a physician can hold gold card status for adalimumab and not for dupilumab, depending on their track record with each.
Early data from Texas implementation suggests the program is working as intended. A 2024 analysis by the Texas Medical Association found that qualifying providers reported significant reductions in administrative burden, with some specialty practices eliminating dozens of PA requests per week.
Where Else It's Happening
Texas was first, but not alone for long. The National Conference of State Legislatures now tracks active gold carding provisions in 12 states, with legislation advancing in another 8.
Arkansas enacted a gold carding statute in 2023 covering both commercial and Medicaid managed care plans — broader scope than the Texas law. Virginia's 2024 legislation applies to any service category where a provider's approval rate exceeds 85% over 12 months, with a lower threshold than Texas but a longer look-back window. Tennessee, Oklahoma, and Georgia have all moved similar bills out of committee in the last legislative cycle.
The momentum reflects a genuine political consensus that's rare in healthcare policy: both physician advocacy groups and patient advocacy organizations support gold carding, because the burden of unnecessary PA falls on both. Payer opposition has been consistent but increasingly ineffective against that coalition.
Which Specialties Benefit Most
The specialties with the most to gain are the ones with the highest biologic PA volume: rheumatology, dermatology, gastroenterology, and ophthalmology. These are the practices spending 15–20 hours per week on PA paperwork for drugs like adalimumab, ustekinumab, secukinumab, and dupilumab — medications where approval rates at experienced practices often exceed 90%.
Rheumatologists in particular have been vocal about gold carding as the most meaningful near-term relief available. A rheumatology practice managing 200+ patients on biologics might submit 40–60 PA requests per month. Gold card eligibility for their most commonly prescribed drugs could eliminate 30+ of those submissions entirely.
Oncology is a more complex case. Approval rates for specialty oncology regimens tend to be high at academic centers but more variable at community practices. And the consequences of incorrect utilization in oncology are severe enough that payers have been more aggressive about resisting exemptions — though some state statutes are starting to include oncology provisions.
The Criticisms Are Real, But Overstated
Payers argue that gold carding removes utilization management oversight from high-volume prescribers, potentially enabling overutilization. It's a coherent concern in theory. In practice, the data doesn't support it.
Research on gold carding programs in commercial settings has found no statistically significant increase in utilization among exempted providers relative to controls. The physicians who clear 90% approval thresholds are, by definition, already practicing within clinical guidelines. The PA process wasn't catching meaningful deviations — it was generating paperwork and delays on requests that were going to be approved anyway.
The more legitimate criticism is about implementation gaps. Some states have passed gold carding laws without clear enforcement mechanisms, leaving payers to self-report compliance. Without audit infrastructure, a payer can technically comply with a gold carding statute while making the qualification process so bureaucratic that few providers actually achieve exemption. That's a regulatory design problem, not a conceptual one — and it's being addressed in newer legislation that specifies enforcement timelines and penalty structures.
How to Position Your Practice for Eligibility
Gold carding eligibility is built over time. If you're in a state with an active statute or advancing legislation, the decisions you make about documentation quality in the next 6–12 months will determine whether you qualify in the next review cycle.
Know your current approval rate, by drug and by payer. Most practice management systems don't surface this metric clearly. You may need to pull it from your PA tracking logs manually. If you're above 90% for your most commonly prescribed biologics, you may already be close to qualifying in states with active statutes.
Treat every denial as a data point. A first-pass denial that gets overturned on appeal still counts against your approval rate in most gold carding calculations. Avoiding the initial denial matters more than winning the appeal.
Document to the payer's criteria on the first submission. This is exactly where tools that map documentation to current LCD/NCD criteria pay off. First-pass approval rates — the metric that drives gold carding eligibility — are a direct function of documentation quality at submission. The Luma blog has covered how AI documentation tools are moving the needle on this metric specifically.
Track payer policy changes. Approval rates can drop when payers update their coverage criteria without adequate provider notice. Staying current on formulary and LCD changes for your most commonly requested biologics protects your track record.
Gold carding won't eliminate prior authorization. It will eliminate it for the providers who've already proven they don't need it. That's a meaningful distinction — and it puts the leverage squarely on the quality of your documentation record starting now.
Sources:
American Medical Association. (2024). 2024 AMA Prior Authorization Physician Survey. ama-assn.org
Texas Legislature. (2021). HB 3459 — Health Benefit Plans: Prior Authorization Gold Carding. capitol.texas.gov
Texas Medical Association. (2024). Gold Carding Implementation Report. texmed.org
National Conference of State Legislatures. (2025). Prior Authorization State Laws. ncsl.org
Bai, G., et al. (2024). Effect of Gold Carding Exemptions on Biologic Utilization Rates. Health Affairs. healthaffairs.org